Why the study?
The success of ECMO in treating systemic lupus erythematosus and the risk factors associated with mortality remain uncertain.
Does extracorporeal membrane oxygenation (ECMO) support result in survival to hospital discharge in pediatric and adult patients with systemic lupus erythematosus?
Does extracorporeal membrane oxygenation (ECMO) support result in survival to hospital discharge in pediatric and adult patients with systemic lupus erythematosus?
ECMO can serve as a viable life-supporting strategy for patients with systemic lupus erythematosus, with approximately half of the patients surviving to hospital discharge.
May support ECMO rescue in refractory SLE; hypothesis-generating and should not yet change practice.
The success of extracorporeal membrane oxygenation (ECMO) in treating Systemic Lupus Erythematosus (SLE) and the risk factors associated with mortality remain uncertain. Methods: We describe the survival outcomes at discharge of the largest SLE cohort on ECMO support. We performed a retrospective cohort study of the Extracorporeal Life Support Organization registry database from 2012 to 2022. Pediatric and adult survivor groups were analyzed using descriptive statistics for the primary study outcome of survival to hospital discharge. Risk predictors for survival were determined by logistic regression. Results: We included 48 children and 368 adults with SLE. Overall, 198 patients (54%) survived to hospital discharge, with a survival of 52% and 47% of pediatric and adult patients, respectively. Conclusion: We conclude that ECMO can be considered a life supporting strategy in pediatric and adult SLE patients.
No takes yet. Share an insight, caveat, or question.
Pereira et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: